Cobenfy

Cobenfy (formerly KarXT) is described as the first and only FDA-approved schizophrenia therapeutic that avoids direct dopamine D2 receptor binding, combining xanomeline tartrate and trospium chloride as its core active ingredients; it was originally developed by Karuna Therapeutics (now part of Bristol Myers Squibb) and received FDA approval on September 26, 2024. VuRoyal (SuQian) Pharmaceutical Company LLC supplies (rather than manufactures) the product, without samples, distributing it across North America, Central/South America, Western Europe, and Eastern Europe.